Bibliographic Details
| Title: |
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes |
| Authors: |
Oliver Schnell, Tadej Battelino, Richard Bergenstal, Andreas L. Birkenfeld, Antonio Ceriello, Alice Cheng, Melanie Davies, Steve Edelman, Thomas Forst, Francesco Giorgino, Jennifer Green, Per-Henrik Groop, Samy Hadjadj, Hiddo J.L.Heerspink, Marcus Hompesch, Baruch Izthak, Linong Ji, Naresh Kanumilli, Boris Mankovsky, Chantal Mathieu, Martin Miszon, Reem Mustafa, Michael Nauck, Roberto Pecoits-Filho, Jeremy Pettus, Kari Ranta, Helena W. Rodbard, Peter Rossing, Lars Ryden, Petra-Maria Schumm-Draeger, Scott D. Solomon, Jan Škrha, Pinar Topsever, Tina Vilsbøll, John Wilding, Eberhard Standl |
| Source: |
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-12 (2023) |
| Publisher Information: |
BMC, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: |
Cardiovascular disease, Chronic kidney disease, Diabetes, GIP/GLP-1 receptor agonist, Heart failure, Obesity, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| More Details: |
Abstract The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year’s focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23–24, 2023 ( http://www.cvot.org ). |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1475-2840 |
| Relation: |
https://doaj.org/toc/1475-2840 |
| DOI: |
10.1186/s12933-023-01788-6 |
| Access URL: |
https://doaj.org/article/d2025af878514bcdbba126d73d787a44 |
| Accession Number: |
edsdoj.2025af878514bcdbba126d73d787a44 |
| Database: |
Directory of Open Access Journals |
|
Full text is not displayed to guests. |
Login for full access.
|
